Prof. Dr. med. Peter Fasching

Professur für Translationale Frauenheilkunde und Geburtshilfe

Expression of the Immunohistochemical Markers CK5, CD117, and EGFR in Molecular Subtypes of Breast Cancer Correlated with Prognosis (2023) Schulmeyer C, Fasching P, Häberle L, Meyer J, Schneider M, Wachter D, Rübner M, et al. Journal article Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging (2023) Gonçalves JPL, Bollwein C, Noske A, Jacob A, Jank P, Loibl S, Nekljudova V, et al. Journal article FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women (2023) Figlioli G, Billaud A, Ahearn TU, Antonenkova NN, Becher H, Beckmann M, Behrens S, et al. Journal article Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis (2023) Fu Z, Brooks MM, Irvin S, Jordan S, Aben KKH, Anton-Culver H, Bandera E, et al. Journal article Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial (2023) Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, Pegram MD, et al. Journal article WebPPG: Feasibility and Usability of Self-Performed, Browser-Based Smartphone Photoplethysmography (2023) Nissen M, Flaucher M, Jäger K, Hübner H, Danzberger N, Titzmann A, Pontones C, et al. Conference contribution Fetal Re-Identification in Multiple Pregnancy Ultrasound Images Using Deep Learning (2023) Gabler E, Nissen M, Altstidl TR, Titzmann A, Packhäuser K, Maier A, Fasching P, et al. Conference contribution, Conference Contribution AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023. (2023) Thill M, Kolberg-Liedtke C, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer JU, Budach W, et al. Journal article, Review article Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. (2023) Slamon DJ, Fasching P, Hurvitz S Journal article, Erratum Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival. (2023) Morra A, Schreurs MA, Andrulis IL, Anton-Culver H, Augustinsson A, Beckmann M, Behrens S, et al. Journal article